Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889055 | 0.82 | CYP2A6 (0.44) | ALDH1A1MAPTPOLBKDM4EHPGD | |
| SCHEMBL18738474 | 0.80 | ALDH1A1 (0.35) | ALDH1A1MAPTPOLBKDM4ERAB9A | |
| SCHEMBL19364799 | 0.79 | TYMS (0.36) | ALDH1A1MAPTTYMS | |
| SCHEMBL28337561 | 0.78 | SMN1; SMN2 (0.47) | ALDH1A1MAPTPOLBKDM4EHPGD | |
| SCHEMBL8595184 | 0.77 | MAPT (0.44) | ALDH1A1MAPTKDM4EHPGDRAB9A | |
| SCHEMBL10053730 | 0.76 | IP6K1 (0.43) | ALDH1A1MAPTPOLBKDM4EHPGD | |
| SCHEMBL25457211 | 0.75 | RAB9A (0.53) | ALDH1A1MAPTPOLBKDM4EHPGD | |
| SCHEMBL12540 | 0.75 | ALDH1A1 (0.50) | ALDH1A1MAPTPOLBKDM4EHPGD | |
| SCHEMBL889003 | 0.75 | ALDH1A1 (0.40) | ALDH1A1MAPTPOLBKDM4EHPGD | |
| SCHEMBL28337562 | 0.75 | KMT2A (0.50) | ALDH1A1MAPTPOLBRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107974143-B | Corrosion-resistant glass flake resin | 江苏罗门扬环保工程有限公司 | 2019-12-20 | — | — | CN | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| CN-107974143-A | Corrosion-resistant glass resin flake | 江苏罗门扬环保工程有限公司 | 2018-05-01 | — | — | CN | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-9156818-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9127021-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-8933110-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8927709-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| EP-1464486-B1 | Lithographic printing method and presensitized plate | FUJIFILM CORP (JP) | 2009-06-17 | — | — | EP | disclosed |
| US-7470712-B2 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470712-B2 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 201/4885MAPT 4471/4885POLB 381/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 201/4885MAPT 4471/4885POLB 381/4885 |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | ALDH1A1 365/4885MAPT 4133/4885POLB 682/4885 |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | ALDH1A1 287/4885MAPT 4073/4885POLB 397/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | ALDH1A1 132/4885MAPT 4391/4885POLB 460/4885 |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | ALDH1A1 365/4885MAPT 4133/4885POLB 682/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | ALDH1A1 287/4885MAPT 4073/4885POLB 397/4885 |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 201/4885MAPT 4471/4885POLB 381/4885 |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | P2RY1, P2RY11, P2RY2 | ALDH1A1 1823/4885MAPT 4033/4885POLB 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.